Can't fill your Capivasertib (Truqap) prescription? Explore FDA-approved alternatives like Alpelisib, Everolimus, and Elacestrant for breast cancer.
If you've been prescribed Capivasertib (brand name Truqap) but are unable to fill your prescription — whether due to insurance issues, cost, specialty pharmacy delays, or other barriers — you may be wondering what other treatment options exist.
The good news is that while Capivasertib is the first and only FDA-approved AKT inhibitor, there are other medications that target similar pathways in HR-positive, HER2-negative breast cancer. This guide walks you through what Capivasertib does, how it works, and the most common alternatives your oncologist might consider.
Important: Never switch or stop a cancer medication on your own. Always discuss alternatives with your oncologist, who can recommend the best option based on your specific tumor type, mutation status, and treatment history.
Capivasertib (Truqap) is a first-in-class AKT inhibitor approved by the FDA in November 2023. It is prescribed for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer that has one or more PIK3CA, AKT1, or PTEN gene alterations.
It is used in combination with Fulvestrant (Faslodex) — a hormonal therapy injection — after the cancer has progressed on at least one previous endocrine-based treatment. The standard dose is 400 mg taken orally twice daily on a 4-days-on, 3-days-off schedule.
For a complete overview, read our article on what Capivasertib is, its uses, and dosage.
Capivasertib works by blocking the AKT protein, a key signaling molecule in the PI3K/AKT/PTEN pathway. This pathway is one of the most commonly altered in breast cancer and plays a major role in cancer cell growth, survival, and resistance to hormonal therapies.
When this pathway is overactive — due to mutations in PIK3CA, AKT1, or loss of PTEN — cancer cells can keep growing even when estrogen is blocked. By inhibiting AKT, Capivasertib helps restore sensitivity to hormonal therapy and slows tumor growth.
For a deeper dive, see our article on how Capivasertib works.
The following medications target overlapping pathways and may be appropriate alternatives depending on your cancer's genetic profile and your treatment history. Your oncologist will help determine which option is best for you.
Drug class: PI3K inhibitor
Manufacturer: Novartis
Approved for: HR-positive, HER2-negative locally advanced or metastatic breast cancer with a PIK3CA mutation, in combination with Fulvestrant
Alpelisib (Piqray) was the first targeted therapy approved specifically for PIK3CA-mutated breast cancer (FDA approval: May 2019). It works by directly inhibiting the PI3K alpha enzyme — one step upstream of AKT in the same signaling pathway that Capivasertib targets.
Key differences from Capivasertib:
Drug class: mTOR inhibitor
Manufacturer: Novartis
Approved for: HR-positive, HER2-negative advanced breast cancer in combination with Exemestane, after failure of Letrozole or Anastrozole
Everolimus (Afinitor) targets mTOR, a protein that sits downstream of the PI3K/AKT pathway. It doesn't require specific gene mutations to be prescribed, making it a broader option for some patients.
Key differences from Capivasertib:
Drug class: Selective estrogen receptor degrader (SERD)
Manufacturer: Stemline Therapeutics (Menarini Group)
Approved for: ER-positive, HER2-negative advanced or metastatic breast cancer with an ESR1 mutation, after at least one line of endocrine therapy
Elacestrant (Orserdu) takes a different approach — instead of targeting the PI3K/AKT pathway, it degrades the estrogen receptor itself. It may be an option if your cancer has an ESR1 mutation (a mutation in the estrogen receptor gene that makes tumors resistant to standard hormonal therapies).
Key differences from Capivasertib:
Drug class: PI3Kα inhibitor
Manufacturer: Genentech (Roche)
Approved for: HR-positive, HER2-negative locally advanced or metastatic breast cancer with a PIK3CA mutation, in combination with Palbociclib and Fulvestrant
Inavolisib (Itovebi) is one of the newest options, approved by the FDA in 2024. Like Alpelisib, it targets PI3Kα specifically. It is used in a triple-drug combination with the CDK4/6 inhibitor Palbociclib (Ibrance) and Fulvestrant.
Key differences from Capivasertib:
The best alternative depends on several factors that only your oncologist can fully evaluate:
Talk to your oncologist about getting additional genetic testing if you haven't already — some alternatives require specific mutations that may not have been tested in your initial workup.
Not being able to fill your Capivasertib prescription is stressful, but it doesn't mean you're out of options. Several FDA-approved alternatives target the same or related pathways and may be effective for your specific cancer type.
Before exploring alternatives, try the strategies in our guide on how to find Capivasertib in stock — you may still be able to get it. And if cost is the main barrier, check out our guide to saving money on Capivasertib.
Whatever path you take, stay in close communication with your oncologist and make decisions together. You deserve the best treatment for your cancer.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
